University of South Carolina College of Pharmacy, Columbia, South Carolina, USA.
Kennedy Pharmacy Innovation Center (KPIC, University of South Carolina College of Pharmacy, Columbia, South Carolina, USA.
Pharmacotherapy. 2021 Feb;41(2):162-171. doi: 10.1002/phar.2506. Epub 2021 Feb 14.
To evaluate the impact of pre-intensive care unit admission (pre-ICU) statin use on all-cause in-hospital mortality and ICU length of stay (LOS).
Retrospective cohort study.
Adult ICUs at tertiary hospitals.
Adult critically ill patients diagnosed with sepsis admitted to the ICUs.
The exposure was pre-ICU statin prescription (statin users); unexposed represented absence of pre-ICU prescription (non-users).
We used the 2001-2012 Medical Information Mart for Intensive Care-III (MIMIC-III) database to determine average treatment effect (ATE) of pre-ICU statin use on 30-day ICU mortality, ICU LOS, and 30-day in-hospital mortality using the Augmented Inverse Propensity Weighted technique (AIPW), after adjusting for confounding factors (age, race, health insurance, corticosteroids use, vital signs, laboratory tests, and Sequential Organ Failure Assessment score (SOFA). We measured 30-day ICU mortality as deaths within 30 days of admission to the ICU, and ICU LOS was measured in fractional days. A 30-day in-hospital mortality was measured as death within 30 days of hospital admission. A total of 8200 patients with sepsis were identified; 19.8% (1623) were statin users, and 80.2% (6577) were non-users. Most were Caucasian, aged 80 years and above, and male. After adjusting for confounding factors, pre-ICU statin use decreased 30-day ICU mortality (ATE, -0.026; 95% confidence interval [CI], -0.048 to -0.009); ICU LOS (ATE, -0.369; 95% Cl, -0.849 to -0.096); and 30-day in-hospital mortality (ATE, -0.039; 95% CI, -0.084 to -0.026) on average compared with non-statin use, respectively. In a stratified analysis, the result for ICU LOS (ATE, -0.526; 95% CI, -0.879 to -0.241) and 30-day in-hospital mortality (ATE, -0.023; 95% CI, -0.048 to -0.002) was consistent among patients admitted to the medical ICU.
Among patients with sepsis admitted to the medical ICU, pre-ICU statin use is causally associated with a decrease in 30-day ICU mortality, ICU LOS, and 30-day in-hospital mortality compared to non-use. This study adds to the totality of evidence on the pleiotropic effect of statin use in patients with sepsis.
评估重症监护病房(ICU)前他汀类药物使用对全因院内死亡率和 ICU 住院时间(LOS)的影响。
回顾性队列研究。
三级医院的成人 ICU。
被诊断为败血症并入住 ICU 的重症危重病患者。
暴露因素为 ICU 前他汀类药物处方(他汀类药物使用者);未暴露因素为无 ICU 前处方(非使用者)。
我们使用 2001-2012 年医疗信息重症监护 III 期(MIMIC-III)数据库,通过增强逆倾向评分加权技术(AIPW),在调整混杂因素(年龄、种族、医疗保险、皮质类固醇使用、生命体征、实验室检查和序贯器官衰竭评估评分(SOFA)后,确定 ICU 前他汀类药物使用对 30 天 ICU 死亡率、ICU LOS 和 30 天院内死亡率的平均治疗效果(ATE)。我们将 30 天 ICU 死亡率定义为 ICU 入住后 30 天内的死亡,ICU LOS 以分数天数表示。30 天院内死亡率定义为入院后 30 天内的死亡。共确定了 8200 例败血症患者;19.8%(1623 例)为他汀类药物使用者,80.2%(6577 例)为非使用者。大多数为白种人,年龄在 80 岁及以上,且为男性。调整混杂因素后,ICU 前他汀类药物使用降低了 30 天 ICU 死亡率(ATE,-0.026;95%置信区间[CI],-0.048 至 -0.009);ICU LOS(ATE,-0.369;95%Cl,-0.849 至 -0.096);和 30 天院内死亡率(ATE,-0.039;95%CI,-0.084 至 -0.026),与非他汀类药物使用者相比。在分层分析中,ICU LOS(ATE,-0.526;95%CI,-0.879 至 -0.241)和 30 天院内死亡率(ATE,-0.023;95%CI,-0.048 至 -0.002)的结果在入住内科 ICU 的患者中是一致的。
在内科 ICU 入住的败血症患者中,与非使用者相比,ICU 前他汀类药物的使用与 30 天 ICU 死亡率、ICU LOS 和 30 天院内死亡率的降低有关。本研究增加了他汀类药物在败血症患者中具有多效性作用的证据总量。